|
|
|
Neurosense Therapeutics Ltd (NASDAQ: NRSN) |
|
Neurosense Therapeutics Ltd
NRSN's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Neurosense Therapeutics Ltd 's sales fell
in IV. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
• More on NRSN's Growth
|
|
Neurosense Therapeutics Ltd
realized a net loss in trailing twelve months.
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.
• More on NRSN's Valuation
|
|
|
|
|
Neurosense Therapeutics Ltd
realized net loss in trailing twelve months.
|
| Company |
| |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.37.
| | | |
